Stay updated on Pembrolizumab After Weekly Paclitaxel Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab After Weekly Paclitaxel Clinical Trial page.

Latest updates to the Pembrolizumab After Weekly Paclitaxel Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This reflects a site version update and does not modify study content.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedFallopian Tube Cancer was added to the conditions list and a new Resources section with the Genetic and Rare Diseases Information Center was added. The page footer now shows Revision: v3.4.2.SummaryDifference0.2%

- Check40 days agoChange DetectedThe page now shows a revision update from v3.4.0 to v3.4.1 with no visible changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check47 days agoChange DetectedGlossary display was added, and metadata related to QC updates was added (Last Update Submitted that Met QC Criteria) along with Revision: v3.4.0. The older QC label variant, No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page footer now shows Revision: v3.3.4, replacing Revision: v3.3.3, which is a minor metadata update that does not affect trial details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedFooter updates: added Revision: v3.3.3 and removed HHS Vulnerability Disclosure and Revision: v3.3.2. These are administrative changes unrelated to the clinical trial details.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab After Weekly Paclitaxel Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab After Weekly Paclitaxel Clinical Trial page.